Erasca Inc (ERAS)

Mar 25, 2025, 4:31 PM EDT - 17 days ago

Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting

Mar 20, 2025, 4:01 PM EDT - 22 days ago

Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results

Jan 31, 2025, 8:00 AM EST - 2 months ago

Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference

Jan 27, 2025, 12:09 AM EST - 2 months ago

Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma

Nov 12, 2024, 4:01 PM EST - 5 months ago

Erasca Reports Third Quarter 2024 Business Updates and Financial Results

Nov 5, 2024, 8:00 AM EST - 5 months ago

Erasca to Present at Upcoming Investor Conferences

Aug 12, 2024, 4:01 PM EDT - 8 months ago

Erasca Reports Second Quarter 2024 Business Updates and Financial Results

May 29, 2024, 8:00 AM EDT - 11 months ago

Erasca to Present at Upcoming Investor Conferences in June

May 21, 2024, 4:05 PM EDT - 11 months ago

Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

May 16, 2024, 8:02 PM EDT - 11 months ago

Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

May 16, 2024, 8:00 PM EDT - 11 months ago

Erasca Announces Pricing of Underwritten Offering of Common Stock

May 8, 2024, 4:01 PM EDT - 1 year ago

Erasca Reports First Quarter 2024 Business Updates and Financial Results

May 7, 2024, 8:00 AM EDT - 1 year ago

Erasca to Present at the Bank of America Health Care Conference

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting

Mar 29, 2024, 11:11 AM EDT - 1 year ago

Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript

Mar 27, 2024, 8:30 PM EDT - 1 year ago

Erasca Announces $45 Million Oversubscribed Private Placement Financing

Mar 27, 2024, 4:01 PM EDT - 1 year ago

Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

Jan 3, 2024, 8:00 AM EST - 1 year ago

Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 11, 2023, 8:00 AM EST - 1 year ago

Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

Nov 28, 2023, 8:00 AM EST - 1 year ago

Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway

Nov 9, 2023, 4:01 PM EST - 1 year ago

Erasca Reports Third Quarter 2023 Financial Results and Business Updates

Nov 8, 2023, 8:00 AM EST - 1 year ago

Erasca to Present at Upcoming Investor Conferences in November

Sep 5, 2023, 8:00 AM EDT - 1 year ago

Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Aug 29, 2023, 8:00 AM EDT - 1 year ago

Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors

Aug 28, 2023, 6:05 AM EDT - 1 year ago

August MDA Breakout Stocks Week 35 - 2023: High-Frequency Gainers To Give You An Edge

AMGN BLUE CAT CSCO CVX DOW IBM

Aug 14, 2023, 3:22 PM EDT - 1 year ago

August MDA Breakout Stocks Week 33 - 2023: Facing The Largest Negative Signal Since February

CVX PUMP

Aug 10, 2023, 4:01 PM EDT - 1 year ago

Erasca Reports Second Quarter 2023 Financial Results and Business Updates

Jun 22, 2023, 4:01 PM EDT - 1 year ago

Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma

Jun 5, 2023, 4:01 PM EDT - 2 years ago

Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

May 31, 2023, 8:00 AM EDT - 2 years ago

Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor

May 25, 2023, 5:00 PM EDT - 2 years ago

Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting

May 16, 2023, 8:00 AM EDT - 2 years ago

Erasca Further Strengthens Business Leadership with Two Key Promotions

May 15, 2023, 4:01 PM EDT - 2 years ago

Erasca Reports First Quarter 2023 Financial Results and Business Updates

May 2, 2023, 8:00 AM EDT - 2 years ago

Erasca to Present at the Bank of America Securities 2023 Health Care Conference

May 1, 2023, 8:00 AM EDT - 2 years ago

Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma

Apr 26, 2023, 5:00 PM EDT - 2 years ago

Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting

Apr 25, 2023, 8:00 AM EDT - 2 years ago

Erasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma

Apr 18, 2023, 9:00 AM EDT - 2 years ago

Erasca Presents Promising Initial Phase 1b Dose Escalation Data from FLAGSHP-1 for ERAS-601 Plus Cetuximab in Patients with Advanced Solid Tumors at the 2023 AACR Annual Meeting

Apr 10, 2023, 8:00 AM EDT - 2 years ago

Erasca Strengthens Clinical and Regulatory Leadership with Two Key Appointments as Company Transitions to Late-Stage Development

Mar 23, 2023, 4:01 PM EDT - 2 years ago

Erasca Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Business Updates

Mar 14, 2023, 4:31 PM EDT - 2 years ago

Erasca Announces Poster Presentation at the 2023 AACR Annual Meeting

Feb 8, 2023, 11:21 AM EST - 2 years ago

Erasca: Potential Strong Upside Ahead

Feb 6, 2023, 8:01 AM EST - 2 years ago

MDA Breakout Stocks Week 6 - February 2023: High-Frequency Gainers To Give You An Edge

BA CACC CAT CELH CRM CVX DIS

Feb 1, 2023, 8:00 AM EST - 2 years ago

Erasca to Present at the Guggenheim Oncology Conference 2023

Jan 4, 2023, 8:00 AM EST - 2 years ago

Erasca to Present at the 41st Annual J.P. Morgan Healthcare Conference

Dec 20, 2022, 8:00 AM EST - 2 years ago

Erasca Announces First Patient Dosed in HERKULES-1 Phase 1b Trial Evaluating ERAS-007 and ERAS-601 MAPKlamp Combination in RAS/MAPK Pathway-Altered Solid Tumors

Dec 9, 2022, 7:34 AM EST - 2 years ago

Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib

Nov 30, 2022, 8:00 AM EST - 2 years ago

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination

Nov 9, 2022, 4:01 PM EST - 2 years ago

Erasca Reports Third Quarter 2022 Financial Results and Business Updates

Oct 12, 2022, 8:00 AM EDT - 2 years ago

Erasca Announces Four Poster Presentations at the Upcoming 34th EORTC-NCI-AACR Symposium